A critical review of anagrelide therapy in essential thrombocythemia and related disorders

Leukemia and Lymphoma

Volumn 46, Issue 5, 2005, Pages 641-650

  Dingli, David ^a   Tefferi, Ayalew ^a  

^a Mayo Clinic   (United States)

Author keywords

Anagrelide; Chemotherpy; Essential thrombocythemia; Myeloproliferative disorders

Indexed keywords

2 AMINO 5,6 DICHLORO 3,4 DIHYDROQUINAZOLINE; ACETYLSALICYLIC ACID; ALPHA INTERFERON; ANAGRELIDE; ANTITHROMBOCYTIC AGENT; BUSULFAN; CHLORAMBUCIL; HYDROXYUREA; INOTROPIC AGENT; MILRINONE; PARACETAMOL; PHOSPHORUS 32; PIPOBROMAN; QUINAZOLINE DERIVATIVE; RL 603; UNCLASSIFIED DRUG;

ABDOMINAL DISCOMFORT; ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LEUKEMIA; ANEMIA; ASTHENIA; BLEEDING DISORDER; CEREBROVASCULAR ACCIDENT; CLINICAL PRACTICE; CLINICAL TRIAL; CLONAL VARIATION; CONGESTIVE HEART FAILURE; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DIGESTIVE SYSTEM ULCER; DISEASE EXACERBATION; DIZZINESS; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG COST; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG EXCRETION; DRUG INDICATION; DRUG INFORMATION; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; EDEMA; ERECTILE DYSFUNCTION; EVIDENCE BASED MEDICINE; FLATULENCE; FLUID RETENTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART PALPITATION; HIGH RISK PATIENT; HUMAN; LEG PAIN; LEG ULCER; LEUKEMIA; LUNG FIBROSIS; LUNG INFILTRATE; MALIGNANT TRANSFORMATION; NAUSEA; NONHUMAN; PANCREATITIS; PATIENT CARE; PHENOMENOLOGY; PIGMENT DISORDER; POLYCYTHEMIA VERA; PRIORITY JOURNAL; PULMONARY HYPERTENSION; REVIEW; RISK REDUCTION; SEIZURE; SKIN PIGMENTATION; SKIN ULCER; THROMBOCYTHEMIA; THROMBOCYTOPENIA; THROMBOCYTOSIS; THROMBOSIS; TREATMENT PLANNING;

CLINICAL TRIALS; HUMANS; HYDROXYUREA; QUINAZOLINES; THROMBOCYTHEMIA, HEMORRHAGIC; THROMBOCYTOSIS;

EID: 20144379068     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1080/10428190400029817     Document Type: Review

References (69)

1. Kaushansky K. The enigmatic megakaryocyte gradually reveals its secrets. Bioessays 1999;21:353-360.
2. Schafer AI. Thrombocytosis. N Engl J Med 2004;350:1211-1219.
3. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clinic Proc 2003;78:174-194.
4. Tefferi A. Recent progress in the pathogenesis and management of essential thrombocythemia. Leukemia Res 2001;25:369-377.
5. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-1265.
6. Tefferi A, Ho TC, Ahmann GJ, Katzmann JA, Greipp PR. Plasma interleukin-6 and C-reactive protein levels in reactive versus clonal thrombocytosis. Am J Med 1994;97:374-378.
7. Barbui T. Indications for lowering platelet numbers in essential thrombocythemia. Semin Hematol 2003;40:22-25.
8. Barbui T, Finazzi G. Risk factors and prevention of vascular complications in polycythemia vera. Semin Thromb Hemost 1997;23:455-461.
9. Barbui T, Finazzi G. Management of essential thrombocythemia. Crit Rev Oncol Hematol 1999;29:257-266.
10. Storen EC, Tefferi A. Long-term use of anagrelide in young patients with essential thrombocythemia. Blood 2001;97: 863-866.
11. Tefferi A, Silverstein MN, Petitt RM, Mesa RA, Solberg LA Jr. Anagrelide as a new platelet-lowering agent in essential thrombocythemia: mechanism of action, efficacy, toxicity, current indications. Semin Thromb Hemost 1997;23:379-383.
12. Boivin P. Indications, procedure and results for the treatment of polycythaemia vera by bleeding, pipobroman and hydroxyurea. Nouv Rev Fr Hematol 1993;35:491-498.
13. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H et al; ECLAP Investigators. Acute leukemia in polycythemia vera. An analysis of 1638 patients enrolled in a prospective observational study. Blood 2004;9:3426.
14. Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.
15. Randi ML, Rossi C, Fabris F, Menapace L, Girolami A. Aspirin seems as effective as myelosuppressive agents in the prevention of rethrombosis in essential thrombocythemia. Clin Appl Thromb/Hemost 1999;5:131-135.
16. Randi ML, Rossi C, Fabris F, Girolami A. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy - a follow-up study in 68 patients. Clin Appl Thromb/Hemost 2000;6:31-35.
17. Cortelazzo S, Finazzi G, Ruggeri M, Vestri O, Galli M, Rodeghiero F, Barbui T. Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis. N Engl J Med 1995;332:1132-1136.
18. Gaver RC, Deeb G, Pittman KA, Smyth RD. Disposition of anagrelide, an inhibitor of platelet aggregation. Clin Pharmacol Ther 1981;29:381-386.
19. Fleming JS, Buyniski JP. A potent new inhibitor of platelet aggregation and experimental thrombosis, anagrelide (BL-4162A). Thromb Res 1979;15:373-388.
20. Gillespie E. Anagrelide: a potent and selective inhibitor of platelet cyclic AMP phosphodiesterase enzyme activity. Biochem Pharmacol 1988;37:2866-2868.
21. Pescatore SL, Lindley C. Anagrelide: a novel agent for the treatment of myeloproliferative disorders. Expert Opin Pharmacother 2000;1:537-546.
22. Abe Andes W, Noveck RJ, Fleming JS. Inhibition of platelet production induced by an antiplatelet drug, anagrelide, in normal volunteers. Thromb Haemost 1984;52:325-328.
23. Lane WJ, Hattori K, Dias S, Peerschke EI, Moore MA, Blanset DL, Lang PC, Petrone M, Rafii S. Anagrelide metabolite induces thrombocytopenia in mice by inhibiting megakaryocyte maturation without inducing platelet aggregation. Exp Hematol 2001;29:1417-1424.
24. Erusalimsky JD, Hong Y, Franklin R. Is the platelet lowering activity of anagrelide mediated by its major metabolite 2-amino-5,6-dichloro-3,4-dihydroquinazoline (RL603)?. Exp Hematol 2002;30:625-626.
25. Mazur EM, Rosmarin AG, Sohl PA, Newton JL, Narendran A. Analysis of the mechanism of anagrelide-induced thrombocytopenia in humans. Blood 1992;79:1931-1937.
26. Solberg LA Jr, Tefferi A, Oles KJ, Tarach JS, Petitt RM, Forstrom LA, Silverstein MN. The effects of anagrelide on human megakaryocytopoiesis. Br J Haematol 1997;99:174-180.
27. Tomer A. Effects of anagrelide on in vivo megakaryocyte proliferation and maturation in essential thrombocythemia. Blood 2002;99:1602-1609.
28. Thiele J, Kvasnicka HM, Fuchs N, Brunnbauer K, Wolkwein N, Schmitt-Graeff A. Anagrelide-induced bone marrow changes during therapy of chronic myeloproliferative disorders with thrombocytosis. An immunohistochemical and morphometric study of sequential trephine. Haematologia 2003;88:1130-1138.
29. Petitt RM, Silverstein MN, Petrone ME. Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders. Semin Hematol 1997;34:51-54.
30. Yoon SY, Li CY, Mesa RA, Tefferi A. Bone marrow effects of anagrelide therapy in patients with myelofibrosis with myeloid metaplasia. Br J Haematol 1999;106:682-688.
31. Voskaridou E, Terpos E, Komninaka V, Eftyhiadis E, Mantzourani M, Loukopoulos D. Chronic myeloid leukaemia with marked thrombocytosis in a patient with thalassaemia major: complete haematological remission under the combination of hydroxyurea and anagrelide. Br J Haematol 2002;116:155-157.
32. Thiele J, Kvasnicka HM. Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients. Ann Hematol 2003;82:148-152.
33. Barbui T, Finazzi G. Treatment indications and choice of a platelet lowering agent in essential thrombocythemia. Curr Hematol Rep 2003;2:248-256.
34. Clark WF, Reid BD, Tevaarwerk GJ. Anagrelide: inhibitor of collagen and forming immune complex induced platelet aggregation and release. Thromb Res 1981;21:215-219.
35. Seiler S, Arnold AJ, Grove RI, Fifer CA, Keely SL Jr, Stanton HC. Effects of anagrelide on platelet cAMP levels, cAMP-dependent protein kinase and thrombin-induced Ca++ fluxes. J Pharmacol Exp Ther 1987;243:767-774.
36. Spencer CM, Brogden RN. Anagrelide. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the treatment of thrombocythaemia. Drugs 1994;47:809-822.
37. Oertel MD. Anagrelide, a selective thrombocytopenic agent. Am J Health Syst Pharm 1998;55:1979-1986.
38. Silverstein MN, Petitt RM, Solberg LA Jr, Fleming JS, Knight RC, Schacter LP. Anagrelide: a new drug for treating thrombocytosis. N Engl J Med 1988;318:1292-1294.
39. Balduini CL, Bertolino G, Noris P, Ascari E. Effect of anagrelide on platelet count and function in patients with thrombocytosis and myeloproliferative disorders. Haematologica 1992;77:40-43.
40. Mazzucconi MG, De Sanctis V, Chistolini A, Dragoni F, Mandelli F. Therapy with anagrelide in patients affected by essential thrombocythemia: preliminary results. Haematologica 1992;77:315-317.
41. Trapp OM, Beykirch MK, Petrides PE. Anagrelide for treatment of patients with chronic myeloid leukemia with a high platelet count. Blood Cells Mol Disease 1998;24:9-13.
42. Petrides PE, Beykirch MK, Trapp OM. Anagrelide, a novel platelet lowering option in essential thrombocythaemia: treatment experience in 48 patients in Germany. Eur J Haematol 1998;61:71-76.
43. Laguna MS, Kornblihtt LI, Marta RF, Michiels JJ, Molinas FC. Effectiveness of anagrelide in the treatment of symptomatic patients with essential thrombocythemia. Clin Appl Thromb/Hemost 2000;6:157-161.
44. Dingli D, Mesa RA, Tefferi A. Myeloid metaplasia with myelofibrosis: an update on pathogenesis and therapy. Intern Med 2004;43:540-547.
45. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 1997;15:173-189.
46. Green A, Campbell P, Buck G, Wheatley K, East C, Bareford D, Wilkins B, Van der Walt J, Reilly J, Harrison C. The Medical Research Council PT1 trial in essential thrombocythemia. Blood 2004;104:96 (abstract 6).
47. Lackner H, Urban C, Beham-Schmid C, Benesch M, Kerbl R, Schwinger W. Treatment of children with anagrelide for thrombocythemia. J Pediatr Hematol/Oncol 1998;20:469-473.
48. Mills AK, Taylor KM, Wright SJ, Bunce I, Eliadis P, Brigden MC, Seeley G, Bashford J, Olsen T, Rentoul A, Kelly C. Efficacy, safety and tolerability of anagrelide in the treatment of essential thrombocythaemia. Aust N Z J Med 1999;29:29-35.
49. Birgergard G, Bjorkjolm M, Kutti J, Larfars G, Lofvenberg E, Markevarn B, Merup M, Palmblad J, Mauritzson N, Westin J, Samuelsson J. Adverse effects and benefits of two years of anagrelide treatment for thrombocythemia in chronic myeloproliferative disorders. Haematologia 2004;89:520-527.
50. Anagrelide Study Group. Anagrelide, a therapy for thrombocythemic states: experience in 577 patients. Am J Med 1992;92:69-76.
51. James CW. Anagrelide-induced cardiomyopathy. Pharmacotherapy 2000;20:1224-1227.
52. Dingli D, Utz JP, Krowka MJ, Oberg AL, Tefferi A. Unexplained pulmonary hypertension in chronic myeloproliferative disorders. Chest 2001;120:801-808.
53. Beressi AH, Tefferi A, Silverstein MN, Petitt RM, Hoagland HC. Outcome analysis of 34 pregnancies in women with essential thrombocythemia. Arch Intern Med 1995;155:1217-1222.
54. Braester A, Laver B. Anagrelide-induced erectile dysfunction. Ann Pharmacother 2002;36:1291.
55. Ruiz-Arguelles GJ, Ruiz-Delgado GJ, Ruiz-Reyes G, Chernoff SG. Anagrelide-induced relapse of a hydroxyurea-induced leg ulcer in a patient with primary thrombocythemia. Mayo Clin Proc 1998;73:1125.
56. Golub R, Adams J, Dave S, Bennett CL. Cost-effectiveness considerations in the treatment of essential thrombocythemia. Semin Oncol 2002;29:28-32.
57. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C. Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 1991;85:124-127.
58. Sterkers Y, Preudhomme C, Lai JL, Demory JL, Caulier MT, Wattel E, Bordessoule D, Bauters F, Fenaux P. Acute myeloid leukemia and myelodysplastic syndromes following essential thrombocythemia treated with hydroxyurea: high proportion of cases with 17p deletion. Blood 1998;91:616-622.
59. Merlat A, Lai JL, Sterkers Y, Demory JL, Bauters F, Preudhomme C, Fenaux P. Therapy-related myelodysplastic syndrome and acute myeloid leukemia with 17p deletion. A report on 25 cases. Leukemia 1999;13:250-257.
60. Furgerson JI, Vukelja SJ, Baker WJ, O'Rourke TJ. Acute myeloid leukemia evolving from essential thrombocythemia in two patients treated with hydroxyurea. Am J Hematol 1996;51:137-140.
61. Tabata M, Imagawa S, Tarumoto T, Ohmine K, Hatake K, Miura Y, Ozawa K. Essential thrombocythemia transformed to acute myelogenous leukemia with t(3;17)(p24; q12), del(5)(q13q34) after treatment with carboquone and hydroxyurea. Jpn J Clin Oncol 2000;30:310-312.
62. Liozon E, Brigaudeau C, Trimoreau F, Desangles F, Fermeaux V, Praloran V, Bordessoule D. Is treatment with hydroxyurea leukemogenic in patients with essential thrombocythemia? An analysis of three new cases of leukaemic transformation and review of the literature. Hematol Cell Ther 1997;39:11-18.
63. Najean Y, Rain JD. Treatment of polycythemia vera: the use of hydroxyurea and pipobroman in 292 patients under the age of 65 years. Blood 1997;90:3370-3377.
64. Nielsen I, Hasselbalch HC. Acute leukemia and myelodysplasia in patients with a Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 2003;74:26-31.
65. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-583.
66. Steensma DP, Tefferi A. Cytogenetic and molecular genetic aspects of essential thrombocythemia. Acta Haematol 2002;108:55-65.
67. Wilson S. Acute leukemia in a patient with sickle-cell anemia treated with hydroxyurea. Ann Intern Med 2000;133:925-926.
68. Al-Jam'a AH, Al-Dabbous IA, Al-Khatti AA, Esan FG. Are we underestimating the leukemogenic risk of hydroxyurea. Saudi Med J 2002;23:1411-1413.
69. Ferster A, Sariban E, Meuleman N. Malignancies in sickle cell disease patients treated with hydroxyurea. Br J Haematol 2003;123:368-369.